Brought to you by 
Akebia closes $41mm Series C to advance lead anemia candidate into Phase III
05 Jun 2013
Executive Summary
Akebia Therapeutics Inc. (treatments for anemia and vascular diseases) raised $41mm through its Series C round that was co-led by Satter Investment Management and Novo AS. Existing investors Novartis Venture Funds, Kearny Venture Partners, Venture Investors LLC, Athenian Venture Partners, Triathlon Medical Ventures, AgeChem Venture, and Sigvion Capital Fund also participated. Akebia plans to use the proceeds to prepare its lead drug candidate AKB6548--currently in Phase IIb for anemia secondary to chronic kidney disease--for Phase III trials.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Akebia closes $41mm Series C to advance lead anemia candidate into Phase III
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice